Schreyger Frank, Scharioth Gabor, Baatz Holger
Augenzentrum Recklinghausen, Erlbruch 34-36, D-45657 Recklinghausen, Germany.
Open Ophthalmol J. 2008 Mar 28;2:57-61. doi: 10.2174/1874364100802010057.
To intraindividually compare the efficacy and safety of the SKGEL(®) implant versus the T-Flux(®) implant in deep sclerectomy.
In a retrospective analysis 17 patients were identified who underwent combined phacoemulsification-deep sclerectomy and implantation of SKGEL(®) in one eye and T-Flux(®) in the contralateral eye.
In eyes with SKGEL(®) the IOP decreased from 20.6+7.3 mm Hg to 14.8+5.3 mm Hg (-5.8 mm Hg or -28.1%), and in eyes with T-Flux(®) from 19.9+7.2 mm Hg to 14.7+3.3 mm Hg (-5.2 mm Hg or -26.1%, no statistically significant difference, p >0.05). Antiglaucoma medications with either implant decreased from initially 2.0+0.8 to 0.3+0.7. A qualified success was found in 17/17 eyes with T-Flux(®) and in 16/17 eyes with SKGEL(®). Complete success was achieved in 14/17 eyes with T-Flux(®) and in 13/17 eyes with SKGEL(®).
The IOP-lowering effect and safety of SKGEL(®) and T-Flux(®) seem to be comparable.
对SKGEL®植入物与T-Flux®植入物在深层巩膜切除术中的有效性和安全性进行个体内比较。
在一项回顾性分析中，确定了17例患者，他们一只眼睛接受了白内障超声乳化联合深层巩膜切除术并植入SKGEL®，对侧眼睛植入T-Flux®。
植入SKGEL®的眼睛眼压从20.6±7.3 mmHg降至14.8±5.3 mmHg（降低5.8 mmHg或28.1%），植入T-Flux®的眼睛眼压从19.9±7.2 mmHg降至14.7±3.3 mmHg（降低5.2 mmHg或26.1%，无统计学显著差异，p>0.05）。两种植入物使用的抗青光眼药物从最初的2.0±0.8降至0.3±0.7。T-Flux®植入的17只眼中有17只取得合格成功，SKGEL®植入的17只眼中有16只取得合格成功。T-Flux®植入的17只眼中有14只取得完全成功，SKGEL®植入的17只眼中有13只取得完全成功。
SKGEL®和T-Flux®的降眼压效果和安全性似乎相当。
